Amir Nashat

Amir Nashat is a Partner in Polaris’ Boston office. He joined Polaris in 2002 and focuses on investments in healthcare. Amir currently represents Polaris as a Director of AgBiome, aTyr Pharmaceuticals (NASDAQ: LIFE), Fate Therapeutics (NASDAQ: FATE), Jnana Therapeutics, Marauder Therapeutics, Metacrine Therapeutics, Morphic Therapeutic, Olivo Labs, Promedior Pharmaceuticals, Scholar Rock, Selecta Biosciences (NASDAQ: SELB), Sofregen Medical, Syros Pharmaceuticals (NASDAQ: SYRS) and TARIS Biomedical.

Prior to joining Polaris, Amir completed his PhD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley. He has been named to the Forbes Midas List of “Top 100 Venture Capitalists.”